Affiliation:
1. Department of Pharmaceutical Services, University of California, Los Angeles 90024.
Abstract
Healthy subjects were given single intravenous doses of ciprofloxacin, azlocillin, and the two drugs simultaneously on separate occasions. High-pressure liquid chromatographic analysis was used to assay the concentrations of both drugs in serum and urine. Pharmacokinetic parameters were calculated by noncompartmental methods. The total body (CL), renal (CLR), and nonrenal (CLNR) clearances; steady-state volume of distribution (Vss); and fractional urinary excretion of ciprofloxacin were all markedly decreased with the simultaneous administration of azlocillin. The disposition of azlocillin was unchanged when it was given with ciprofloxacin compared to when it was given alone. The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively. This interaction resulted in significantly higher and more prolonged concentrations of ciprofloxacin in serum, which may be beneficial in the treatment of serious gram-negative bacterial infections, but it could also produce greater toxicity or result in more pronounced effects on oxidative drug metabolism of other medications.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference11 articles.
1. Ciprofloxacin, azlocillin, ceftizoxime, and amikacin alone and in combination against gram-negative bacilli in an infected chamber model;Bamberger D. M.;J. Antimicrob. Chemother.,1986
2. The acylampicillins: mezlocillin, piperacillin, and azlocillin;Drusano G. L.;Rev. Infect. Dis.,1984
3. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis;Johnson M.;J. Infect. Dis.,1987
4. Jusko W. J. 1989. Guidelines for collection and analysis of pharmacokinetic data p. 9-54. In W. E. Evans J. J. Schentag and W. J. Jusko (ed.) Applied pharmacokinetics-principles and therapeutic drug monitoring 2nd ed. Applied Therapeutics Inc. San Francisco.
5. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function;Kampf D.;Clin. Pharmacol. Ther.,1984
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Optimizing Therapeutic Drug Monitoring in Pregnant Women: A Critical Literature Review;Therapeutic Drug Monitoring;2023-01-19
2. Beta-Lactam Antibiotics;Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions;2018
3. Renal Drug Transporters and Drug Interactions;Clinical Pharmacokinetics;2017-02-16
4. Beta-Lactam Antibiotics;Drug Interactions in Infectious Diseases;2011
5. Therapeutic implications of renal anionic drug transporters;Pharmacology & Therapeutics;2010-05